We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Rua Life Sciences Plc | LSE:RUA | London | Ordinary Share | GB0033360586 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.0% | 19.50 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 18.00 | 21.00 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Plastics,resins,elastomers | 2.18M | -2M | -0.0903 | -2.16 | 4.33M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 19.50 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 24/11/2023 | 10:46 | ALNC |  RUA Life Sciences shares fall on worsened performance in first half |
| 24/11/2023 | 07:00 | UKREG | RUA Life Sciences PLC Trading Update |
| 20/11/2023 | 14:03 | ALNC | RUA Life Sciences shares soar as testing and new deals progress |
| 20/11/2023 | 07:00 | UKREG | RUA Life Sciences PLC Strategy Update |
| 10/11/2023 | 13:30 | UKREG | RUA Life Sciences PLC Holding(s) in Company |
| 01/11/2023 | 17:30 | UKREG | RUA Life Sciences PLC Change of Nominated Adviser and Broker |
| 01/9/2023 | 07:04 | UKREG | RUA Life Sciences PLC Directorate Change |
| 23/8/2023 | 15:18 | UKREG | RUA Life Sciences PLC Result of AGM |
| 22/8/2023 | 07:57 | ALNC | RUA Life Sciences shares rise on upbeat trading update |
| 22/8/2023 | 06:00 | UKREG | RUA Life Sciences PLC AGM Statement and Trading Update |
Rua Life Sciences (RUA) Share Charts1 Year Rua Life Sciences Chart |
|
1 Month Rua Life Sciences Chart |
Intraday Rua Life Sciences Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 29/11/2023 | 13:29 | RUA Life Sciences - Elast-Eon Enabled MedTech | 3,192 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2023-11-29 16:27:49 | 20.85 | 959 | 199.95 | O |
| 2023-11-29 16:27:15 | 20.88 | 10,000 | 2,088.00 | O |
| 2023-11-29 16:11:25 | 20.25 | 2,000 | 405.00 | O |
| 2023-11-29 15:59:26 | 20.95 | 100 | 20.95 | O |
| 2023-11-29 15:44:57 | 20.95 | 1,193 | 249.93 | O |
| Top Posts |
|---|
Posted at 29/11/2023 08:20 by Rua Life Sciences Daily Update Rua Life Sciences Plc is listed in the Plastics,resins,elastomers sector of the London Stock Exchange with ticker RUA. The last closing price for Rua Life Sciences was 19.50p.Rua Life Sciences currently has 22,184,798 shares in issue. The market capitalisation of Rua Life Sciences is £4,326,036. Rua Life Sciences has a price to earnings ratio (PE ratio) of -2.16. This morning RUA shares opened at - |
Posted at 24/11/2023 11:01 by drradcliffe What's interesting is Equity Development weren't expecting a trading update. They seemed to think the 20/11/23 Strategy Update replaced a trading update.From their note 21/11/23: "Strategy Update In place of the trading statement which is usually released at this time of year, and ahead of RUA Life Sciences’ interim results, RUA has released a more material - and very well-received - strategy update." "Sticking to its objectives In place of a trading statement that updates investors on the progress of its revenue-generating businesses and its products in development, RUA’s strategy update has been well-received by investors because it outlines the path of the business to greater and earlier revenues than we had expected in RUA Contract Manufacture and RUA Structural Heart. The strategy also lowers the risks for investors compared to funding the development of RUA’s products solely by an equity offering, at a time where life science markets are depressed and the potential dilution punitive." Does this mean the market itself wasn't expecting this trading update? I wonder whether it was a very recent decision to do this in order to stabilise the share price, and specifically on a Friday morning to get rid of the short term traders? If you are going to arrange a small placing, the last thing you want is a highly volatile share price. |
Posted at 21/11/2023 10:27 by nimbo10 Share price brought to it's knees on rights issue worries, with that now gone, back to normal valuations and to top it quicker time to profitability.Also like statement of substantial upside from yesterday's rns. If Bill is to be believed. Sicilian no chance of fund raise as market will loose complete trust in management after yesterday's statement. "The limiting factor however is the cost of capital placed upon RUA because of the depressed share price. Not only would dilution relate to the interest in the Vascular project but the substantial upside potential from both RUA Contract Manufacture and RUA Structural Heart would be limited for current shareholders" |
Posted at 21/11/2023 10:19 by edmonda Strategy Update, sticking to its objectives - new note from Equity Development (link here: In place of the trading statement which is usually released at this time of year, and ahead of RUA Life Sciences’ interim results, RUA has released a more material - and very well-received - strategy update. In place of a trading statement that updates investors on the progress of its revenue-generating businesses and its products in development, RUA’s strategy update has been well-received by investors because it outlines the path of the business to greater and earlier revenues than we had expected in RUA Contract Manufacture and RUA Structural Heart. The strategy also lowers the risks for investors compared to funding the development of RUA’s products solely by an equity offering, at a time where life science markets are depressed and the potential dilution punitive. RUA Contract Manufacture, the contract manufacturer of medical devices using implantable fabrics with a biocompatible Elast-Eon coating, is responding to a formal bid request that could result in around £2m in revenues, with much of that recuring on an annual basis. Thus, RUA’s board’s objective of doubling the scale of the contract manufacturing business in the medium term is on track. |
Posted at 20/11/2023 11:51 by langland A few quick notes on today's RNS.Obviously I am happy to see the progress on the 3 fronts after the dire share price performance so far this year. CM Turnover on track to double though no deals signed yet but it does seem to vindicate previous Board comments. HV 'Rather than incur the full cost of developing a valve directly, our strategic focus is now to accelerate the commercial potential of RUA Structural Heart by making the composite available to the heart valve industry for incorporation into next generation valves. The Company expects to shortly formalise an agreement to provide composite material to a large heart valve company for its own testing and now that an attractive data pack is available on the composite, RUA intends to broaden this further through the industry' I thought it worth repeating the final paragraph because it highlights 2 things. First, a major player (think Edwards) will shortly formalise agreement to test the HV with possibility of some upfront cash (though not stated). Secondly, the possibility that the HV technology could be thrown open to whole industry. I can't help but think that the likes of Edwards and Medtronic won't like that. VD It depends how any deal is structured but a mixture of flexibility on % and money upfront to cover back costs. And finally we need to remember that RUA is absolutely dwarfed by all the companies it is speaking to. So, what price a takeout by a corporation keen on safeguarding RUA IP from competitors? |
Posted at 13/11/2023 13:00 by langland A few observations with regard to the heart valve project (HV)---As a small shareholder from about 12 years ago I do not remember such positive comments or results from the HV beginning with the results announcement in July followed by the AGM statement. The latter is reproduced here for ease of reference-- 'RUA Structural Heart, which has been undertaking research and development activities into the creation of a polymeric heart valve, has made an outstanding breakthrough in the development of a synthetic leaflet material for the manufacture of heart valves. As well as demonstrating that it has the flexibility to perform as a heart valve leaflet, our new composite material has now achieved the important milestone of completing 400 million cycles (equivalent to 10 years in man and twice regulatory requirements) of fatigue testing. As at the time of the release of the Group's annual report, only 200 million cycles had been completed. The blood contacting properties of Elast-Eon, combined with the flexibility, durability and mechanical properties of the composite, mean that the new composite may well be suitable to be used in valve designs that are currently in the market. As such, the route to commercialisation for the RUA composite is no longer dependant on developing and testing our own valve design but could be more near term by making the composite available to other manufacturers. Having been approached, we have recently agreed to provide a major player with material for evaluation to initially confirm some of our in-house test results.' In addition to this we have had the benefit of bones's debrief from the AGM itself which again is reproduced for ease of ref. 'Heart valve The internal excitement about the leaflet material that has been created is palpable. John Ely (the ex-FDA NED who has brought several HV’s to market himself) explained in somewhat technical terms about the huge additional market that would open up to the four main players in heart valves if they could make TAVI valves with a material that is markedly thinner yet stronger than existing technologies. It seems it can be produced to only 90 microns wide, which is much thinner than current technologies, yet the material comprises textiles and Elast-Eon bound almost as one, seemingly almost unbreakable which is a major advance in avoiding stress tears and cracks. It would enable them to make smaller valves that would suffer less stress when compressed for delivery via the artery. They would also no longer have to rely on a limited source of supply of gelatin (which could disappear with a bovine virus outbreak in the outback!) and the patient population would expand with the longer durability of the material. The company is finalising a broad patent application and hopes to submit it this week. Hopefully they receive acceptance in a few weeks then they will supply a basic sample of the material to one of the majors that has asked for it. Although this initial sample supply is not for payment, no IP data about the product is being released. Once the major wants to take it to the next step, then it gets more commercial. That is my understanding of what I heard. To put this all in context the TAVI market was forecast to grow to over 300k procedures by 2025. If Rua's new leaflet material is adopted, this by itself could increase the size of the market because the size of the implant would be that much smaller and thus lend itself to those people who are too frail or old to have either open heart surgery or current type of TAVI. Edwards and Medtronic (mkt caps of $39bn and £90bn respectively) are the market leaders and their heart valves command prices in the $35k-$40k range. Hopefully, it is one of them to whom RUA refers in the AGM statement. Polymeric heart valves have already been allowed in man (Foldax) so RUA's HV or leaflets may well see a faster route to market in the hands of one of the majors - as mentioned in the AGM statement. If the HV cam pass muster, the numbers are staggering for a company the size of RUA. We could see an up front licensing payment followed by a royalty stream of say 5% (or $2000) for each valve implanted. Based upon an extremely modest use of 5k implants per annum the income would be $10mn. The alternative, and more likely in my opinion, is for the sale of the HV company lock, stock and leaflet. This may all seem blue sky but the developments of the last few months have far surpassed anything I have seen before. Understandably, the market has overlooked or ignored all of the foregoing in the last few months. The next update is going to be important for all sorts of reasons but I am hoping we will see further development progress in respect of the HV. |
Posted at 08/9/2023 19:16 by hedgehog11 What is the cost of a raise - it's only a few posts back but someone suggested half a million? I have no clue but if that's true, why bother raising a million just to keep half of it.At 10p they would also be asking existing investors to buy 1 share for every 2 they own. That means EVERY shareholder buying half their existing shares. Admittedly a cheaper undertaking than the potential price they've already paid. A serious partnership for RUA would help encourage investors. It is possible someone will partner with them and the share price will recover multiples, but most recently RUA reported that the bloke in charge of the regulatory approval process has left the board with immediate effect in favour of another opportunity whilst still being employed for handover. That doesn't suggest the approval is a cast iron as RUA have implied. I agree that RUA should be protecting the profitable businesses but if they mothball Vascular and HV, they'll have redundancy costs, I imagine that being quite huge! |
Posted at 28/7/2023 16:28 by bones Langland, just caught up with your posts (2912, 2916, etc). I agree that at this stage it is looking like a case of working out what needs selling off (if possible) to get some cash and stability back on the rails. As you suggest, the sale of the vascular division might work if someone better capitalised can take on the project and its assets.RUA says with just the pilot plant operational, the business would be worth around £25M but of course a sale now would be pre-trials so any buyer would want a big discount to cover the expected costs of trials plus a risk premium to cover the possibility of trial problems. Maybe £10M then for the whole project as it stands? That would still be a clear £5M profit on the project over its development period of 5 years to date. Given that the addressable market is large, £10M might be worth paying by someone for the huge upside to them if all goes well. The outcome would be valuable cash for RUA and a future Elasteon royalty stream from any future sales of grafts by the new owner. Some staff would also leave with the business too saving on those costs. The safety of cash in hand and the removal of the millstone of trials uncertainties and costs from the neck of RUA would be a blessing for the share price. Will the egos of the board even contemplate this? This was the basis of the reboot in 2018 after all and a lot has been achieved on a small budget. They should do it though. Not only because “needs must” right now but it would free up the group to concentrate on its core licensing side. It sounds as though there are some breakthroughs occurring in the heart valve and heart leaflet technology and staff efforts could better be directed towards that area having been freed of the burden that Vascular has become. Being free of dealing with that monster called the FDA (a common graveyard for small UK Med-Techs and pharmas) would also be a relief in my opinion. Would Corcym be a problem (if they were not the buyer)? I don’t see why since they get nothing from the products if they are not trialled and marketed. Businesses make things work for them. The group has done wonders with what it has achieved on a relative pittance in terms of its graft and HV technologies but that’s when to hive off the work to the bigger boys where the big bucks are needed and available. Alternatively, if it is felt that the vascular breakthrough is worth persevering with, then sell the apparently ready made contract manufacturing business which seems to be worth a good £10M according to the directors based on an EBITDA multiple and it is already a profitable enterprise. That should appeal to more buyers? This would mean the R&D activities would have to once again buy in the facilities from the contract manufacturing division that would now be a third party (as it was prior to the buyout of RUA Medical but at least RUA would continue to earn royalties on any elasteon being used in the products. Again, savings on staff that leave with the business would be a benefit. That’s two possibilities there without necessarily relying on a placing (if feasible). Surely the board have been looking at these options over the last year given that the 2022 webinar presentations made a point of highlighting the valuations of each business division? I took that to mean they were all potentially available for sale for anyone looking in and not just to make shareholders feel better about the wide discount in share price to those values. Time is now short so the board needs to be radical rather than worrying about pride that maybe their grand ideas have also come up short. Not easy but running businesses never is but maybe now is the time for the board to prove themselves and right this ship. |
Posted at 26/7/2023 06:24 by buywell3 The_Real_Mr_Big26 Jul '23 - 07:11 - 2877 of 2879 ------ did you not read" The Board has concluded that further financing is required and has taken advice from the Company's Nomad and Broker on the current state of the equity market and the chances of a successful fundraise." Hence --- Cash Raise Cometh methinketh See 2, Going concern The Board has to consider that the Going Concern principle is appropriate for the preparation of these accounts. At 31 March 2023, the Group had cash and cash equivalents of £1.48m (2022: £2.96m) and, as at the date of signing these Financial Statements, the cash balance was £0.9m. RUA Life Sciences has two cash-generative units (RUA Biomaterials and RUA Contract Manufacture). These cash-generating units provide a healthy Gross Margin (89% and 49%), and contributions to Group operating loss were £493,000 and £794,000. The Group has two cash-consuming units (RUA Vascular and RUA Structural Heart), and both these units require further investment before commercialisation and cash generation can be achieved. The investment will chiefly be for a GLP animal study and Human Clinical Trials for RUA Vascular. The Board anticipates the requirement for additional funding over the course of the financial year as the internal cash generation will not cover the additional investment required. The Board has considered the current cash position, reviewed budgets and profit and cash flow forecasts over the going concern period (to October 2024) along with sensitivity analyses and made appropriate enquiries. The Board has concluded that further financing is required and has taken advice from the Company's Nomad and Broker on the current state of the equity market and the chances of a successful fundraise. The_Real_Mr_Big26 Jul '23 - 07:11 - 2877 of 2879 0 1 0 Good update. Looks like we are managing OK. All the deramper crying about a cash raise for the last 2 years have been baseless. There's definitely one coming at some point, looking at burn vs cash in hand right now, but it even looks like we have a few months to get the best possible deal on it. buywell3 - 23 Aug 2022 - 22:59:34 - 2270 of 2880 RUA Life Sciences - Elast-Eon Enabled MedTech - RUA The opportune share price for a cash raise might imo have just been missed |
Posted at 25/6/2023 13:50 by bones IN VIVO ANIMAL TRIAL FOR VASCULAR GRAFTIn the interim results statement dated 12th December 2022, the following was stated in regard to the initial “in vivo” animal trials which we were told would be measuring the healing process of the implanted grafts at 1, 3 and 6 month intervals, as required by the FDA. ”While the preliminary in vivo work is currently underway, we continue to assess the best time to start the clinical trial. RUA will advise in more detail on the expected costs and revised timescales in due course but in the meantime is actively exploring opportunities to finance at least part of the clinical stages through non-dilutive funding routes and grant finance.” The implication then is that, for the earlier implantations in this current in vivo work, the six months will already have been reached. Possibly some of the animal work will have continued as more of them are implanted with grafts for this trial. In the previous in vivo trial in 2021, RUA used 12 animals (9 sheep implanted with RUA grafts and 3 with the control graft from Terumo). I suspect more would be needed this time so it could be ongoing for the later animals implanted. Turning to the very recent trading update, we had this stated: ”As previously reported, RUA has been undertaking a "pre-sub" with the FDA and RUA is delighted to report that agreement has very recently been reached with the FDA on protocols for a GLP animal trial and a human clinical trial of the RUA vascular graft. This has been a lengthy process but felt to be worthwhile as it limits the risk of the FDA asking for additional information or testing after submission. During this period of discussion with the FDA, RUA has taken the opportunity to undertake additional development and testing on the graft range with a view to improving performance and maximising manufacturing yields. A detailed work plan has been prepared for the agreed testing regime and quotations received from third party test houses for the required work. The clinical study will involve around 120 patients and further details regarding the costings and timings of this work will be announced in due course.” Taken at face value, this latest statement seems to be saying that the FDA has only just approved the structure of both the animal trial and the human trial. It also states that more work has been done refining and improving the grafts that RUA eventually want to market. This too suggests that the grafts to be tested ought to be the best ones RUA can produce. This basically begs the question, what happened to the in vivo studies that were started in or before December 2022 and has that work now been consigned to the dustbin so that a new, improved, FDA-approved animal trial can now begin? Or, has that original work continued and morphed into the studies that will be presented to the FDA? If so, which version of the grafts went into the earlier animals seeing as the grafts have continued to be refined? Surely, in an official trial, the status of the grafts implanted have to be consistent throughout the animal and human trials? It’s probably lost in the messaging, but it doesn’t entirely give clarity about where RUA currently is in the timeline on the in vivo work. They are not helping themselves or shareholders here! |
Posted at 08/6/2023 13:22 by edmonda FY2023 Trading Update - welcome regulatory and R&D progress (and divisional reorganisation)Full details in our note published this morning: Summary: RUA Life Sciences trading update included Group revenues and year-end cash position were modestly ahead of our estimates, with other figures mostly in-line. The highlight of the trading update was the agreement with the FDA on the requirements for the GLP animal study and 120-patient clinical trial required to secure US approval of RUA’s vascular graft. It is clear that RUA is on a pathway to the US approval of its vascular graft which should not be a surprise. RUA Contract Manufacture and RUA Biomaterials both have US customers with approved products. The trading update also provided detail on RUA’s Structural Heart polymeric heart valve product, noting the high bar that heart valves need to reach in terms of their mechanical properties, durability and functionality. RUA’s composite heart valve appears to be meeting these milestones and the current design was proposed as one that could be supplied to other companies. In a subsequent announcement, RUA provided the details of a reorganisation of the Group resulting in its key experimental product businesses – RUA Structural Heart Limited and RUA Vascular Limited – into stand-alone subsidiaries 100% owned by the Group. We applaud this move on a transparency basis which fits with the trading update’s reporting on the segmented sales and net profit margins of RUA’s revenue-generating businesses, RUA Biomaterials and RUA Contract Manufacture. We would caution investors not to jump to the conclusion that one or more of RUA’s segmented divisions could be divested despite the illustrative basis of our valuation being as whole-product acquisitions. Instead, as the timelines for the vascular graft and heart valve products are different, the hive down of the two businesses allows the value and risks of each to be appreciated and provides visibility on where any possible future fundraisings are invested. We await RUA’s final FY 2023 results in mid-July to update our financials and valuation. For now, our valuation remains at £121.0m (545p per share). |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
